

CITATION REPORT

List of articles citing

First 12 patients with coronavirus disease 2019 (COVID-19) in the United States

DOI: 10.1101/2020.03.09.20032896

»»»

Source: <https://exaly.com/paper-pdf/85602483/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
36	Inferred duration of infectious period of SARS-CoV-2: rapid scoping review and analysis of available evidence for asymptomatic and symptomatic COVID-19 cases. <i>BMJ Open</i> , 2020 , 10, e039856	3	160
35	Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing. <i>Nature</i> , 2020 , 586, 113-119	50.4	405
34	The trade-off dilemma in pharmacotherapy of COVID-19: systematic review, meta-analysis, and implications. <i>Expert Opinion on Pharmacotherapy</i> , 2020 , 21, 1821-1849	4	3
33	Evaluation of Current Therapies for COVID-19 Treatment. <i>Microorganisms</i> , 2020 , 8,	4.9	9
32	A Focus on the Nowadays Potential Antiviral Strategies in Early Phase of Coronavirus Disease 2019 (Covid-19): A Narrative Review. <i>Life</i> , 2020 , 10,	3	4
31	Does remdesivir have any neuropsychiatric adverse effects?. <i>Irish Journal of Psychological Medicine</i> , 2021 , 38, 313-314	3	2
30	Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19. <i>ACS Central Science</i> , 2020 , 6, 672-683	16.8	397
29	Materials science approaches in the development of broad-spectrum antiviral therapies. <i>Nature Materials</i> , 2020 , 19, 813-816	27	27
28	Clinical Characteristics of COVID-19 in Patients With Liver Injury. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 2846-2847	6.9	7
27	A Review on SARS-CoV-2 Virology, Pathophysiology, Animal Models, and Anti-Viral Interventions. <i>Pathogens</i> , 2020 , 9,	4.5	38
26	Epidemiology of Covid-19. <i>New England Journal of Medicine</i> , 2020 , 382, 1869	59.2	23
25	Hepatic and gastrointestinal involvement in coronavirus disease 2019 (COVID-19): What do we know till now?. <i>Arab Journal of Gastroenterology</i> , 2020 , 21, 3-8	1.7	81
24	Exploring Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors for Organ Protection in COVID-19. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	14
23	A group of homoeopathic medicines for COVID-19: A systematic review of clinical features. <i>Indian Journal of Research in Homoeopathy</i> , 2021 , 15, 123	0.5	1
22	Therapeutic Strategies in the Management of COVID-19. <i>Frontiers in Molecular Biosciences</i> , 2020 , 7, 636738	3.8	8
21	COVID-19: molecular pathophysiology, genetic evolution and prospective therapeutics-a review. <i>Archives of Microbiology</i> , 2021 , 203, 2043-2057	3	4
20	Screening and Molecular Modeling Evaluation of Food Peptides to Inhibit Key Targets of COVID-19 Virus. <i>Biomolecules</i> , 2021 , 11,	5.9	2

19	Gastrointestinal and hepatic diseases during the COVID-19 pandemic: Manifestations, mechanism and management. <i>World Journal of Gastroenterology</i> , 2021 , 27, 4504-4535	5.6	2
18	Characteristics of SARS-CoV-2 testing for rapid diagnosis of COVID-19 during the initial stages of a global pandemic. <i>PLoS ONE</i> , 2021 , 16, e0253941	3.7	0
17	Revealed pathophysiological mechanisms of crosslinking interaction of affected vital organs in COVID-19. <i>Comparative Clinical Pathology</i> , 2021 , 30, 1-17	0.9	1
16	Potential Effects of Coronaviruses on the Liver: An Update. <i>Frontiers in Medicine</i> , 2021 , 8, 651658	4.9	5
15	Clinical Characteristics and Diagnostic Challenges of COVID-19: An Update From the Global Perspective. <i>Frontiers in Public Health</i> , 2020 , 8, 567395	6	10
14	Estimating false-negative detection rate of SARS-CoV-2 by RT-PCR.		61
13	A Large-scale Drug Repositioning Survey for SARS-CoV-2 Antivirals. 2020 ,		40
12	Persistent viral shedding of SARS-CoV-2 in faeces - a rapid review.		3
11	Therapeutic effectiveness of interferon-alpha 2b against COVID-19: the Cuban experience.		9
10	Gastrointestinal and hepatic manifestations of COVID-19 infection: Lessons for practitioners. <i>World Journal of Meta-analysis</i> , 2020 , 8, 348-374	0.5	2
9	COVID-19: etiology, clinical picture, treatment. <i>Russian Journal of Infection and Immunity</i> , 2020 , 10, 421-445	4.5	21
8	Liver injury in COVID-19: The hepatic aspect of the respiratory syndrome - what we know so far. <i>World Journal of Hepatology</i> , 2020 , 12, 1182-1197	3.4	12
7	: urine is not urine in corona times. <i>Future Oncology</i> , 2020 , 16, 2899-2902	3.6	1
6	Pharmacological management of COVID-19. <i>Journal of Pediatric Critical Care</i> , 2020 , 7, 42	0	2
5	Identification and Development of Therapeutics for COVID-19. <i>MSystems</i> , 2021 , e0023321	7.6	5
4	Gastroenterological and Hepatic Manifestations of Patients with COVID-19, Prevalence, Mortality by Country, and Intensive Care Admission Rate: Systematic Review and Meta-analysis.		
3	Efficacy and safety of the sofosbuvir/velpatasvir combination for the treatment of patients with early mild to moderate COVID-19.. <i>Scientific Reports</i> , 2022 , 12, 5771	4.9	0
2	A Review of the Presence of SARS-CoV-2 in Wastewater: Transmission Risks in Mexico. <i>International Journal of Environmental Research and Public Health</i> , 2022 , 19, 8354	4.6	0

- 1 Safety and sagacious use of remdesivir: Paramount focus on contemporary perspectives. **2022**, 6, 1 ○